This review paper, published in Frontiers in Pharmacology, provides a comprehensive synthesis of research from 2019 to 2024 regarding the therapeutic potential of polysaccharides in treating various liver diseases and their emerging role as targeted drug delivery systems.
TL;DR
Polysaccharides derived from natural sources are emerging as potent, low-toxicity alternatives to traditional liver medications by targeting multiple pathways, including oxidative stress, inflammation, and the gut-liver axis. Beyond their direct bioactivity, their unique physicochemical properties allow them to serve as "homing" shells for delivering toxic chemotherapeutics directly to liver tumors.
What Problem Does This Paper Address?
Liver diseases—ranging from drug-induced injury (DILI) and fatty liver (NAFLD/ALD) to cirrhosis and hepatocellular carcinoma (HCC)—account for approximately 2 million deaths annually. While drugs like silymarin are commonly used, they often suffer from limited efficacy or adverse reactions during long-term treatment.
The authors address the urgent need for "multi-target" therapies. Because liver pathogenesis is complex—involving a "multi-hit" of metabolic dysfunction, oxidative stress, and immune overreaction—single-molecule drugs often fall short. Polysaccharides, which are complex carbohydrates found in medicinal plants and fungi, offer a promising solution due to their high biocompatibility and ability to modulate several biological pathways simultaneously.
Methods
As a systematic review, the authors analyzed primary research published between January 2019 and October 2024. They queried major databases (Web of Science, PubMed, CNKI) using keywords related to polysaccharides and specific liver pathologies. The paper categorizes the findings into:
- Therapeutic effects across six major disease models.
- Mechanistic pathways (e.g., Nrf2/ARE, TLR4/NF-κB, and AMPK).
- Bio-nanotechnology applications, specifically the engineering of polysaccharide-based micelles and nanoparticles for drug delivery.
Datasets
While the paper does not introduce a new raw dataset, it tabulates and synthesizes results from dozens of experimental studies. These studies primarily utilize:
- In vivo models: BALB/c and C57BL/6 mice, SD and Wistar rats.
- Disease induction: APAP (Acetaminophen), alcohol, high-fat diets (HFD), and $CCl_4$.
- Cell lines: HepG2, Hep3B, and SMMC-7721 (for cancer research).
Key Insights and Ideas
- The Gut-Liver Axis: One of the most significant insights is that polysaccharides don't just work on the liver directly. They often treat the liver by repairing the "leaky gut" (intestinal barrier) and modulating microbiota, such as increasing the abundance of beneficial Akkermansia bacteria, which reduces the flow of inflammatory endotoxins to the liver.
- Multi-Pronged Mechanism: Unlike targeted inhibitors, polysaccharides act as broad-spectrum regulators. They simultaneously boost antioxidant enzymes (via the Nrf2 pathway), suppress pro-inflammatory cytokines (via NF-κB inhibition), and regulate lipid metabolism (via the AMPK pathway).
- Structural Determinants: The paper highlights that a polysaccharide's "power" is tied to its structure. For instance, higher uronic acid content and specific molecular weights are positively correlated with better hepatoprotective outcomes, though the exact "structure-activity code" remains partially elusive.
- Natural Homing Devices: Polysaccharides like those from Angelica sinensis have a natural affinity for asialoglycoprotein receptors on hepatocytes. This allows researchers to create "Trojan Horse" delivery systems that carry toxic drugs like Doxorubicin directly to the liver, sparing other organs (like the heart) from toxicity.
Key Results
The review summarizes several quantitative and qualitative breakthroughs:
- DILI: Polysaccharides from Smilax china L. and Phellinus linteus significantly reduced liver enzymes (ALT/AST) by upregulating the Nrf2/ARE antioxidant defense.
- NAFLD/ALD: Multiple studies showed a reduction in liver lipid accumulation and a reversal of "fatty" phenotypes by modulating the PPAR$\alpha$/CPT-1 pathway.
- Cancer (HCC): Polysaccharides were shown to induce apoptosis in hepatoma cells by regulating the Bcl-2/Bax ratio and inhibiting tumor angiogenesis (VEGF pathway).
- Drug Delivery: Polysaccharide-based nanocarriers significantly improved the solubility of Curcumin and reduced the cardiotoxicity of Doxorubicin while increasing the drug's concentration at the tumor site.
Limitations and Future Work
Despite the optimism, the authors acknowledge several hurdles:
- Bioavailability: Polysaccharides are large, polar molecules, making them difficult for the body to absorb efficiently.
- Structural Complexity: Because they are natural products, their composition can vary based on the source, region, and extraction method, making standardization difficult.
- The "Clinical Gap": The vast majority of current evidence is derived from rodent models or cell cultures. There is a critical lack of large-scale human clinical trials to confirm these effects in patients.
- SAR Mapping: Future research needs to focus on the precise Structure-Activity Relationship (SAR) to determine exactly which sugar chains or branches are responsible for specific therapeutic effects.
Summary updated